Compare BK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BK | VRTX |
|---|---|---|
| Founded | 1784 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3B | 115.7B |
| IPO Year | N/A | 1991 |
| Metric | BK | VRTX |
|---|---|---|
| Price | $120.61 | $441.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 27 |
| Target Price | $128.75 | ★ $501.42 |
| AVG Volume (30 Days) | ★ 3.6M | 1.4M |
| Earning Date | 01-13-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 27.59 | N/A |
| EPS | 7.40 | ★ 14.22 |
| Revenue | ★ $20,112,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $7.48 | $10.93 |
| Revenue Next Year | $3.94 | $8.44 |
| P/E Ratio | ★ $16.40 | $31.03 |
| Revenue Growth | 8.43 | ★ 10.33 |
| 52 Week Low | $70.46 | $362.50 |
| 52 Week High | $125.89 | $519.68 |
| Indicator | BK | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 43.16 |
| Support Level | $118.50 | $436.69 |
| Resistance Level | $125.89 | $487.52 |
| Average True Range (ATR) | 2.31 | 11.28 |
| MACD | 0.00 | -3.63 |
| Stochastic Oscillator | 49.91 | 20.47 |
Bank of New York Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors, delivering investment management and services in 35 countries and more than 100 markets. BNY is the largest global custody bank in the world, with $52.1 trillion in under custody or administration (as of December 2024), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY's asset-management division manages about $2.0 trillion in assets.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.